Safety alert issued by FDA with the use of Tarceva

Discussion Board Forums Chemotherapy & More Safety alert issued by FDA with the use of Tarceva

Viewing 5 posts - 1 through 5 (of 5 total)
  • Author
    Posts
  • #23150
    jeffg
    Member

    Violarob in Texas—- It goes along with what we have always said; different chemo works differently on different people. We are all so unique and individual.
    Jeff

    #23149
    violarob
    Member

    I’m sorry to hear about many people having side effects from Tarceva. Maybe my case is unusual, but I have had no side effects, and have been on it for 6 months. My tumors continue to be stable; no growth at all.

    Violarob in Texas

    #23148
    dldct
    Member

    Just one other note on Tarceva. My mom was on it for about 3 months and she developed a serious problem breathing. It caused inflammation in her lungs. They admitted her to the hospital on Monday and put her on a ventilator. She is beginning to do better now and hopefully will come home in a few days. This is something that only 5% or so of the people develop (or so they say) but something important to watch out for.

    Dawn

    #23147
    jeffg
    Member

    RANK


    Thank You so much for your post. It confirms my suspicions of another chemo drug, or at least in my own personal feelings, that I had, of it making matters worse for my liver. I just saw my Oncologist on Thursday and he asked if I was going to try anymore chemo after radiation? I said I might. He suggested Tarceva. I said I’m not taking that one. He asked why? I told him it has not been getting very good reviews in my opinion. So he suggested carboplatin again, as I wasn’t on it that long back in 05. Thanks again for being so alert and posting this safety notice.

    God Bless,
    Jeff G.

    #1594
    rank
    Member

    I came across the following alert:
    It can be found on http://www.hemonctoday.com/article.aspx?rid=31571

    OSI Pharmaceuticals Inc. and Genentech Inc. issued a safety information letter for erlotinib (Tarceva) after the results of a pharmacokinetic study revealed cases of hepatic failure, hepatorenal syndrome and fatalities. Erlotinib is used in the treatment of non

Viewing 5 posts - 1 through 5 (of 5 total)
  • You must be logged in to reply to this topic.
©2019 - All Rights Reserved, Cholangiocarcinoma Foundation